Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 5NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Central Nervous System Neoplasms 7Lymphoma 6Glioblastoma 6Gliosarcoma 5Hodgkin Disease 4Astrocytoma 4Burkitt Lymphoma 3Recurrence 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Glioma 2Waldenstrom Macroglobulinemia 1Plasmablastic Lymphoma 1Neutropenia 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1HIV Infections 1Dendritic Cell Sarcoma, Interdigitating 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Doxorubicin 4Cyclophosphamide 4Vincristine 3Rituximab 3Prednisone 3Dexamethasone 3Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Melphalan 2Interferon-alpha 2Etoposide 2Cytarabine 2Bortezomib 2tositumomab I-131 1liposomal amphotericin B 1fludarabine 1denileukin diftitox 1Watchful Waiting 1Vancomycin 1VAP-cyclo protocol 1Thalidomide 1Tazobactam 1Piperacillin, Tazobactam Drug Combination 1Piperacillin 1Palliative Care 1Nutritional Support 1Moxifloxacin 1Morphine 1Methotrexate 1Lapatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Waldenstrom Macroglobulinemia × Carmustine × Clear all
NCT00723658 2015-03-06

S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

SWOG Cancer Research Network

Phase 2 Withdrawn
Lymphoid

Lymphoma, Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡